Cadrenal Therapeutics, Inc. (CVKD)
| Market Cap | 13.27M -57.0% |
| Revenue (ttm) | n/a |
| Net Income | -11.89M |
| EPS | -5.57 |
| Shares Out | 3.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,912 |
| Open | 4.190 |
| Previous Close | 4.190 |
| Day's Range | 4.190 - 4.508 |
| 52-Week Range | 4.145 - 15.990 |
| Beta | 1.61 |
| Analysts | Strong Buy |
| Price Target | 27.67 (+542.0%) |
| Earnings Date | May 7, 2026 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CVKD stock is "Strong Buy." The 12-month stock price target is $27.67, which is an increase of 542.00% from the latest price.
News
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX cou...
Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference
CAD-1005, a first-in-class 12-LOX inhibitor, targets the root cause of HIT, a rare but severe immune-mediated thrombotic disorder with high mortality and hospital costs. A pivotal registration trial is planned following positive phase II data, with potential for broader applications.
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo...
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombo...
Cadrenal Therapeutics Quarterly report: Q1 2026
Cadrenal Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Cadrenal Therapeutics Earnings release: Q1 2026
Cadrenal Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Cadrenal Therapeutics Slides: Investor presentation
Cadrenal Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA
Cadrenal Therapeutics (CVKD) announced a regulatory milestone after completing its End-of-Phase 2 meeting with the FDA and receiving guidance on key elements of the Phase 3 pivotal trial for CAD-1005,...
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand...
Cadrenal Therapeutics Registration statement: Registration filing
Cadrenal Therapeutics filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders
06:04 EDT Cadrenal Therapeutics (CVKD) files to sell 1.18M shares of common stock for holders
Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Cadrenal Therapeutics (CVKD) to $13 from $32 and keeps a Buy rating on the shares to account for updated share count and…
Cadrenal Therapeutics Inc trading halted, volatility trading pause
15:29 EDT Cadrenal Therapeutics (CVKD) Inc trading halted, volatility trading pause
Cadrenal Therapeutics Inc trading resumes
15:34 EDT Cadrenal Therapeutics (CVKD) Inc trading resumes
Cadrenal Therapeutics Annual report: Q4 2025
Cadrenal Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Cadrenal Therapeutics Earnings release: Q4 2025
Cadrenal Therapeutics released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal's near-term development priority; broader 12-LOX platform remains a longer-term opportunity E...
Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum
CAD-1005, a novel IV therapy for HIT, is advancing to phase III after promising phase II results and strong safety data. The drug targets a major unmet need, holds Orphan Drug and Fast Track status, and may have broader applications in diabetes and obesity.
Cadrenal Therapeutics highlights research on 12-LOX inhibition
Cadrenal Therapeutics (CVKD) highlighted recent scientific findings demonstrating the potential of its first-in-class 12-lipoxygenase, 12-LOX, inhibitor, CAD-1005, to target inflammatory consequences ...
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments for life-threatening immune and thromboti...
Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion
Cadrenal Therapeutics (CVKD) provided additional perspectives on development opportunities following its recent pipeline expansion with the addition of 12-LOX inhibitors. As previously announced, Cadr...
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla., Mar...
Cadrenal Therapeutics announces Phase 2 results for CAD-1005
Cadrenal Therapeutics (CVKD) announced results from a Phase 2 trial evaluating CAD-1005 in patients with heparin-induced thrombocytopenia, a severe pro-thrombotic reaction to heparin, the most commonl...
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2...
Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
The discussion highlighted a portfolio targeting critical gaps in anticoagulation, with VLX-1005 and Tecarfarin advancing for rare, high-risk patients. VLX-1005's novel 12-LOX inhibition approach in HIT, regulatory advantages, and upcoming milestones position it as a key near-term value driver.